This page shows the latest AZD1222 news and features for those working in and with pharma, biotech and healthcare.
British pharma company AstraZeneca also told Reuters that its COVID-19 vaccine, AZD1222, should be effective against the new UK variant.
On 11 December 2020, AZ announced "a clinical trial programme to assess the safety and immunogenicity of a combination of AZD1222, developed by AstraZeneca and Oxford University, and Sputnik V, developed ... The interim analysis for efficacy of the
British pharma company AstraZeneca also told Reuters that its COVID-19 vaccine, AZD1222, should be effective against the new variant. ... AZD1222 contains the genetic material of the SARS-CoV-2 virus spike protein, and the changes to the genetic code
In the control group – those who did not receive AZD1222 – ten participants were hospitalised due to COVID-19, with two volunteers developing severe disease, including one fatal case. ... The company will also continue to evaluate AZD1222 in a large
Last month, AZ announced that the Oxford University-partnered vaccine candidate AZD1222 demonstrated an average efficacy of 70%, with up to 90% efficacy in a subgroup who received a half dose
WHO’s immunisations director says ‘more than a press release’ is needed
More from news
Approximately 6 fully matching, plus 17 partially matching documents found.
About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...